Pharmaceutical industry news

Trump Order Directs Federal Push on Psychedelic Drug Research and Review

UFRJ participa de pesquisa sobre ampliação do acesso à saúde e redução de desigualdades

Parestesia: cos’è e quali sono i sintomi

ACRP Launches 2026–27 Scholarship and Grant Application Season

Doctoral Mobility: Results of the Call for Projects between Université Paris Cité and the University of Toronto

Orexin discoverers awarded prestigious Lasker award

Luma locks down 15-year, $410M fund for life science investments

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

Nutriband CEO Gareth Sheridan to Attend Inaugural Nasdaq LaB Biotech Summit

Tyra rolls toward pivotal cancer study even as stock deflates

Five Years at BIO: Mexico Gaining Ground in Global Biotech

Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovation

Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data

Ocugen doses first patient in phase 3 GA gene therapy trial

Viral haemorrhagic fever: ACDP algorithm and guidance on management of patients

Specialist guidance on the management (including infection control) of patients with viral haemorrha...

ImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updates

Suddenly this summer, biotech breaks open with drug approvals, IPOs. Will it last?

Glicemia: valori e misurazione

Nordic biotech CEOs reveal secret to major funding and pharma deals

Don't Ignore The Insider Selling In BioMarin Pharmaceutical

Nitrosamines: from detection to understanding

From Molecule to Product: How Integrated Drug Product Solutions Are Becoming a Critical Driver of Biologics Commercialization

ANMAT dispuso la baja de habilitación de la firma REHUE S.A. y prohibió sus productos importados

PharmaSource podcast: How EXOZ Is Running a 10-CDMO RFP for CDMO Selection

A paid pilot will test Trinity Biotech cooling fluids in AI data centers

Over £1.5 billion to help NHS withstand year-round pressure

More than 950 projects will make NHS hospitals safer, more resilient and better equipped to care for...

A narcolepsy drug showed median reductions of up to 88.8% in sudden muscle-loss attacks.

UKRI investment supports new UK Space Strategy

From AI to the death of the default: what cancer science will look like in the next decade

Le CHU de Lille lance une grande campagne marque employeur

Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2025 to August 2026

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Atmospheric NOₓ may contribute to NDSRI formation, study shows

Novartis: Back-to-Back Phase 3 Failures for Pelacarsen and Del-Desiran Send Shares Sliding

International Research on Bioengineering of the Mitochondrial Genome

World Health Expo to showcase trillion-dollar growth across pharma, biotech, longevity and wellness at 2027 edition

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, May 2026 to May 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, April 2026 to April 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, March 2026 to March 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, February 2026 to February 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, June 2026 to June 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, July 2026 to July 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, August 2026 to August 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2026 to September 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, October 2026 to October 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, January 2026 to January 2027

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Novartis Pays $50M Milestone as MRT-6160 Enters Phase 2 for Sjögren’s Disease

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, December 2025 to December 2026

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, November 2025 to November 2026

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, October 2025 to October 2026

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2025 to September 2026

Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resista...

Rezera Announces Ruvonoflast Met its Primary Inflammation

Molecular Surface Design Achieves Over 100 Millionfold Tuning of Porous Liquid Viscosity

血友病A治療薬ヘムライブラを創製した中外製薬の研究者3名が世界的権威のある米国の科学賞「ラスカー賞」を受賞 ～独自の着想で治療体系を変えたバイスペシフィック抗体の発明が評価～

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors - Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach –

Veradius Unity and BV Pulsera Mobile C-Arm System-9in. and 12in. Versions

Air bubbles may develop in the monoblock oil when there is a prolonged period between manufacture an...

Philips Ingenia, Achieva and Intera MR Systems

Philips has become aware of a software issue affecting Philips Magnetic Resonance (MR) imaging syste...

NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program

Court of Appeals hears oral arguments in Louisiana abortion pill lawsuit

Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN)

Ganesh Chaturthi 2026: Mumbai’s 12,000 Ganesh mandals under FDA scanner over prasad, bhandara food...